Dr. Jonathan Peterson has recently received a materials grant from Dualsystems Biotech AG to identify the unknown receptor for CTRP3. This grant will allow Dr. Peterson to use new top-of the line, newly described technology termed TriCEPS-based ligand-receptor capture (LRC-TriCEPS).
Dr. Petersons previous work has shown that the novel protein CTRP3 prevents fatty liver disease. However the mechanism by which CTRP3 is able to protect the liver from excess fat accumulation is unknown. Fatty liver disease is leading cause of liver related mortality in the United States, and currently there are no effective pharmaceutical treatments available. Identification of the cell receptor for CTRP3 is an important step needed to understand the mechanism by which CTRP3 is able to protect the liver from excess fat accumulation. Further, identification of the receptor is the essential step needed to take what we learn about CTRP3 and translate it into novel clinical pharmaceuticals to treat fatty liver disease.